S

Sanofi

Global pharma company; vaccines and R&D

Externally Sponsored Research Specialist

Full-TimeUpdated on 10/23/2026Deadline 11/15/26
No salary listed
Mid
Bachelor's
Hyderabad, Telangana, India
In PersonTravel required as per business need.
Biology & BiotechClinical Research Operations

About the job

Requirements
  • At least 3 years of experience in medical or clinical operations and at least 2 years of professional experience managing projects in an international environment.
  • A degree in a scientific discipline or related degree, with substantial project management and/or project leadership experience.
  • High proficiency with Microsoft Office, including Outlook, Excel, Word, and PowerPoint.
  • Excellent spoken and written English.
Responsibilities
  • Manage incoming externally sponsored research requests by liaising with global and local medical teams and ensuring requests are handled according to internal procedures.
  • Assess sponsors and investigators during study-outline review, including sponsor qualification checks.
  • Receive external study proposals submitted in the Sanofi system; evaluate and analyze requests, perform quality checks, identify whether a proposal is a Medical or research and development study, identify the franchise where applicable, identify reviewers, and liaise with them to ensure appropriate review by the relevant panel.
  • Set up and manage Scientific Review Committee meetings to review Company Sponsored Studies and Externally Sponsored Collaborations, Investigator-Sponsored Studies, and Global Health Studies according to the established operating model.
  • Perform quality control of assigned externally sponsored research, ensure data accuracy in the Sanofi system, and liaise with appropriate stakeholders.
  • Manage externally sponsored research records and document filing for audits and internal control.
  • Review and approve Fair Market Value assessments, ensuring appropriate evaluation criteria and industry-benchmarked compensation are applied when studies engage services for Sanofi companies.
  • Provide project management support for Confidential Disclosure Agreement creation and management.
  • Support protocol quality-control activities and externally sponsored research study management in iEnvision.
  • Align with team members and key stakeholders to integrate and prioritize projects across the portfolio and ensure compliance with approved processes.
  • Support team initiatives and objectives, identify and recommend process improvements and initiatives, and participate in company initiatives to add business value.
  • Analyze project objectives and deliverables to identify risks and efficiencies, and ensure resources, budgets, and project timelines are optimized and realistic.
  • Track relevant project key performance indicators, proactively identify issues, and propose actions to achieve the project plan.
  • Evaluate alternative solutions to resolve or mitigate risks and issues, escalating them as appropriate.
  • Contribute operational expertise to the overall strategy and ensure operational excellence and compliance readiness.
  • Lead governance and stakeholder alignment for Scientific Review Committee meetings; manage documentation and compliance and act as the primary liaison for study requestors and global partners.
  • Serve as the primary point of contact for Fair Market Value and Confidential Disclosure Agreement processes.
  • Review externally sponsored research budgets and verify total costs against industry benchmarks.
  • Work closely with stakeholders from various global business units, Sanofi Business Operations activity teams, and Sanofi Business Operations leadership.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...